



InteliSwab™ COVID-19 Rapid Test makes testing easy.

A remarkably simple COVID-19 rapid antigen test

- Self-collected, visually-read lateral flow test
- Both symptomatic and asymptomatic¹ use
- Intuitive workflow: just “swab, swirl, and see”
- Gentle lower nasal swab
- < 1 minute of “hands-on” time, 30-minute time to result

3 InteliSwab™ configurations:

- Over-the-counter Home Test (2-pack serial test)
- Prescription Home Test (1-pack)
- Point-of-care bulk packs (healthcare professional use)



FDA EMERGENCY USE AUTHORIZED

This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

¹Asymptomatic use for InteliSwab™ COVID-19 Rapid Test and Rapid Test Pro only

Dramatically simplify COVID-19 testing with IntelliSwab™

Simple and easy-to-use

- Just 3 simple steps: swab, swirl and see your result
- Intuitive workflow has no difficult or confusing steps
 - ✓ No dropper and precise number of drops required
 - ✓ No complex manipulation of swab
 - ✓ No alignment of test strip onto Instructions For Use for interpretation
 - ✓ No risk of damaging unprotected assay strip with accidental touching
- No batteries, instruments or smartphones required to get a result
- Clinically proven easy-to-use

Quick and efficient

- Workflow requires < 1 minute of active, hands-on time
- IntelliSwab™ provides test results in hand in just 30 minutes
- No lab send out needed

Practical

- 9-month shelf life initially on all tests
- No need for ancillary supplies such as nasal swabs or readers

Accurate

- Overall test performance: Positive Percent Agreement 84%, Negative Percent Agreement 98%
- Clinical performance proven with untrained and unproctored lay-users

Testing will be critical throughout all stages of epidemic transition



Diagnose and Triage

Individuals with symptoms or contact tracing



Screening

Enable attendance at public settings, workplaces, events



Surveillance

Monitoring in public settings or with vulnerable populations

Configuration	IntelliSwab™ COVID-19 Rapid Test	IntelliSwab™ COVID-19 Rapid Test Rx	IntelliSwab™ COVID-19 Rapid Test Pro
	Over-the-Counter	Prescription Home Test	Point-of-Care
Catalog Number	1001-0616	1001-0620	1001-0614
Test devices	24 x 2-test kits	24 x 1-test kits	25 tests